BigHat Biosciences
An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
$75MSeries C
ParticipantCC
Catalio Capital Management
Activity from announced rounds
Activity in this selectionUnited States · Oct 19, 2026 · Sep 20, 2026
Catalio Capital Management is an investment manager whose official company communications identify BigHat Biosciences and Basecamp Research.
Recorded funding activity
BigHat combines AI and synthetic biology to engineer antibody therapeutics. Basecamp builds biological models from genomic data for therapeutic design, while Enveda discovers biologically active molecules from nature. The financings represent different routes from biological data to experimental medicines.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $386M 2 disclosed · full round size, not this investor’s share